June 27 (Reuters) - The U.S. Food and Drug
Administration said on Friday that it had eliminated the risk
evaluation and mitigation strategies (REMS) for currently
approved Bristol-Myers Squibb's ( BMY ) CAR T cell
immunotherapies.